Nuveen Asset Management LLC Buys 164,915 Shares of Annexon, Inc. (NASDAQ:ANNX)

Nuveen Asset Management LLC lifted its stake in Annexon, Inc. (NASDAQ:ANNX - Free Report) by 6.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,720,485 shares of the company's stock after purchasing an additional 164,915 shares during the period. Nuveen Asset Management LLC owned 2.55% of Annexon worth $13,956,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the stock. E Fund Management Co. Ltd. boosted its position in Annexon by 36.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company's stock valued at $79,000 after buying an additional 4,086 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Annexon by 6.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 63,402 shares of the company's stock worth $325,000 after purchasing an additional 4,092 shares during the last quarter. Comerica Bank lifted its position in Annexon by 22.7% during the 4th quarter. Comerica Bank now owns 23,183 shares of the company's stock valued at $119,000 after purchasing an additional 4,283 shares during the period. Wellington Management Group LLP boosted its stake in shares of Annexon by 1.8% in the 4th quarter. Wellington Management Group LLP now owns 268,166 shares of the company's stock valued at $1,376,000 after purchasing an additional 4,806 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of Annexon by 4.3% in the 4th quarter. Rhumbline Advisers now owns 141,852 shares of the company's stock valued at $728,000 after purchasing an additional 5,854 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ANNX. HC Wainwright cut their price objective on shares of Annexon from $20.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Needham & Company LLC reduced their price target on Annexon from $16.00 to $11.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th.

Annexon Price Performance

Shares of Annexon stock traded down $0.12 during trading on Friday, hitting $2.07. 227,892 shares of the company were exchanged, compared to its average volume of 1,549,136. The firm has a market capitalization of $226.56 million, a P/E ratio of -1.97 and a beta of 1.24. The firm's fifty day moving average price is $1.82 and its 200 day moving average price is $3.35. Annexon, Inc. has a 1-year low of $1.28 and a 1-year high of $7.85.

Annexon (NASDAQ:ANNX - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.07). As a group, equities research analysts anticipate that Annexon, Inc. will post -0.96 earnings per share for the current year.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.